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Although smoking prevalence has declined in recent years, certain subpopulations 
continue to smoke at disproportionately high rates and show resistance to cessation 
treatments. Individuals showing cognitive and affective impairments, including emotional 
distress and deficits in attention, memory, and inhibitory control, particularly in the context 
of psychiatric conditions, such as attention-deficit hyperactivity disorder, schizophrenia, 
and mood disorders, are at higher risk for tobacco addiction. Nicotine has been shown to 
improve cognitive and emotional processing in some conditions, including during tobacco 
abstinence. Self-medication of cognitive deficits or negative affect has been proposed 
to underlie high rates of tobacco smoking among people with psychiatric disorders. 
However, pre-existing cognitive and mood disorders may also influence the development 
and maintenance of nicotine dependence, by biasing nicotine-induced alterations in 
information processing and associative learning, decision-making, and inhibitory control. 
Here, we discuss the potential forms of contribution of cognitive and affective deficits to 
nicotine addiction-related processes, by reviewing major clinical and preclinical studies 
investigating either the procognitive and therapeutic action of nicotine or the putative 
primary role of cognitive and emotional impairments in addiction-like features.
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iNTRODUCTiON
Smoking tobacco remains the most preventable cause of morbidity and mortality worldwide. Nicotine 
is the main psychoactive component of tobacco responsible for its addictive properties and modifies 
the function of the brain via its interaction with the nicotinic acetylcholine receptors (nAChRs) 
(1, 2). Drug addiction is a complex psychiatric disorder, and there are individual differences in the 
vulnerability to develop this pathology that can be conceptualized at different levels interacting with 
each other, such as environmental, genetic, and psychological contributions. Only a percentage of 
individuals starting to smoke tobacco eventually develop an addiction (3). In particular, there is a high 
prevalence of smoking in patients with psychiatric disorders. However, it has been difficult to define 
in clinical studies the nature of the causal interactions between these pathologies. The psychological 
and neural processes that underlie addiction have been shown to overlap with those that support 
cognitive and emotional functions. One critical question is to which extent psychiatric conditions 
may pre-date smoking or develop after chronic exposure to nicotine. One of the main limitations 
to resolve this issue is the difficulty to conduct longitudinal prospective studies in humans and to 
control for co-use of multiple substances in patient cohorts. As a consequence, preclinical research 
TAble 1 | Mental disorders/personality trait and nicotine addiction-
related features in humans.
Mental disorder/
personality trait
Nicotine addiction-
related features
Reference
Cognitive 
impulsivity
↗ initiation of smoking 
behavior in adolescents
Audrain-McGovern et al. 
(12)
↗ smoking relapse Sheffer et al. (13)
Motor impulsivity ↗ subjective rewarding 
effects of nicotine
Perkins et al. (14)
↗ risk for regular tobacco 
smoking
Anokhin and Golosheykin 
(15)
Impulsivity 
(subtype 
undetermined)
↗ explicit expectancies 
about nicotine reward
Doran et al. (16)
↗ initiation of smoking lipkus et al. (17)
Novelty/sensation 
seeking
↗ risk to become regular 
smoker
Audrain-McGovern et al. 
(18)
↗ sensitivity to the initial 
reinforcing effect of 
nicotine
Perkins et al. (14)
↗ initiation of smoking lipkus et al. (17)
↘ smoking-cessation 
success
Kahler et al. (19), Batra et al. 
(20)
ADHD ↗ future smoking Fuemmeler et al. (21), 
Tercyak et al. (22)
↗ relapse to smoking Humfleet et al. (23)
↘ onset of regular 
smoking
lambert and Hartsough 
(24), Kollins et al. (25)
↗ withdrawal symptoms Pomerleau et al. (26), 
McClernon et al. (27), Kollins 
et al. (28)
↗ motivation for cigarette 
puffs
Kollins et al. (28)
↗ nicotine dependence wilens et al. (29)
Major depression ↗ smoking and risk of 
nicotine dependence
Fergusson et al. (30)
↘ likeliness to quit Rohde et al. (31)
↘ odds of smoking 
abstinence
Glassman et al. (32), Hitsman 
et al. (33)
Depression 
symptoms
↗ smoking initiation escobedo et al. (34)
↗ progression to regular 
smoking
Killen et al. (35), 
Patton et al. (36), 
wang et al. (37)
Anxiety disorders ↗ smoking rates Lasser et al. (38), Ziedonis 
et al. (39)
↗ nicotine dependence Piper et al. (40)
↗ resistance to 
pharmacotherapy for 
abstinence
Piper et al. (40)
↘ rates of abstinence Piper et al. (41)
↗ withdrawal symptoms Weinberger et al. (42)
PTSD symptoms ↗ tobacco dependence Beckham et al. (43), 
Thorndike et al. (44), Feldner 
et al. (45), Greenberg et al. 
(46)
↘ rates of quitting and 
time to relapse after 
quitting
Lasser et al. (38), Hapke et al. 
(47), Beckham et al. (48)
↗ nicotine withdrawal 
symptoms
Dedert et al. (49)
Schizophrenia ↗ tobacco smoking, 
nicotine dependence and 
difficulties to quit
Lasser et al. (38)
References in bold describe longitudinal studies.
ADHD, attention-deficit hyperactivity disorder; PTSD, posttraumatic stress disorder.
2
Besson and Forget Psychiatric Disorders and Nicotine Addiction
Frontiers in Psychiatry | www.frontiersin.org September 2016 | Volume 7 | Article 160
has increasingly aimed at identifying distinctive endophenotypes 
that may predispose individuals to nicotine addiction-like pro-
cesses and/or that are influenced by nicotine exposure. Animal 
models can never encompass entirely the complexity of the 
psychological processes underlying behavior related to addiction 
and other psychiatric conditions in humans with full face and 
construct validities. Yet, they provide a valuable tool to precisely 
control the environmental (and genetic) context, the conditions 
of drug delivery, and to determine whether beforehand drug con-
sumption influences the risk to develop specific endophenotypes 
or whether pre-existing endophenotypes confer vulnerability to 
addiction, through the implementation of longitudinal studies. 
They also allow detailed investigations of the distinct stages of 
addiction that may be connected to some endophenotypes to 
varying extents. In fact, the defining criteria of addiction are still 
a matter of debate, and this pathology exhibits complex dynam-
ics with different stages, from the initiation and maintenance of 
drug taking to a switch toward a loss of control over drug intake, 
compulsive drug taking and seeking, i.e., despite negative conse-
quences, together with high rate of relapse after abstinence (4–8). 
With the use of experimental models of distinct addiction-like 
behaviors in addition to epidemiological and neurocognitive 
studies in human subjects, specific behavioral endophenotypes 
of presumed genetic origin have been identified as significant 
risk factors for drug addiction according to different modalities. 
Understanding the causal relationship between nicotine addic-
tion and psychiatric disorders may significantly contribute to 
the treatment of comorbid psychiatric conditions and smoking. 
This review will describe and discuss both clinical and preclinical 
studies that brought significant insight in that matter.
TObACCO SMOKiNG, PeRSONAliTY 
TRAiTS, AND PSYCHiATRiC CONDiTiONS
Vulnerability to addiction varies across individuals. Thus, 
although many people experiment with drugs of abuse, most 
do not develop drug addiction as defined by diagnostic criteria 
for substance-use disorder (9). Individual differences in vulner-
ability to abuse are thought to exist before the first drug experi-
ence and clinical evidence suggests that these differences reflect 
both genetic and environmental determinants, including social 
influences, as well as their interaction [see Ref. (10) for review]. 
Cigarette smoking is the leading preventable cause of death in 
the Western world (11) with a prevalence considerably higher in 
individuals with psychiatric diagnosis. In this part of the review, 
we will examine non-exhaustively the relationships described in 
clinical studies between smoking behavior, personality traits, and 
psychiatric disorders, such as impulsivity, novelty/sensation seek-
ing, attention-deficit hyperactivity disorder (ADHD), depression, 
and anxiety disorders (see Table 1).
impulsivity, Novelty Seeking, and 
Tobacco Smoking
Impulsivity is a heritable and multifaceted psychiatric construct 
defined by the tendency to engage in inappropriate, premature, 
poorly planned, and unduly risky actions without adequate 
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forethought about the potential consequences of this behavior 
(50–53). It has been associated with drug addiction, including 
tobacco smoking (54).
Current theories differentiate between motor and cognitive 
aspects of impulsive behavior. Motor impulsivity reflects a failure 
in motor inhibition leading to impulsive actions and can be 
assessed by the ability to exert volitional control over a response 
that has already been initiated or rendered prominent with exten-
sive training. This type of impulsivity can be notably measured 
in the “stop-signal reaction time task,” in which subjects are 
trained to respond as quickly as possible but must inhibit their 
response when a stop signal is presented, or in a go/no go task 
(54). While several studies linked deficits in this type of impulsiv-
ity with alcohol (55), cocaine (56, 57), and methamphetamine 
(58) addiction, the data about tobacco addiction are less clear. 
Thus, tobacco smoking has been shown to decrease inhibitory 
control in a stop-signal task, where an increased number of errors 
during the stop signal and increased stop latencies were observed 
(59). But, another study reported no baseline differences between 
smokers and non-smokers in the same task (60). In addition, an 
increase in failure in response inhibition in both stop signal and 
go/no go tasks was observed after nicotine deprivation in tobacco 
smokers (61, 62), suggesting that nicotine withdrawal induces 
deficits in inhibitory control. Interestingly, a recent longitudinal 
prospective study showed that alterations in neural correlates of 
response inhibition in adolescents increase the risk for subse-
quent regular cigarette smoking (15), suggesting that functional 
brain correlates of response inhibition can be used as a marker of 
risk for tobacco addiction.
Cognitive aspects of impulsivity include response inhibition, 
delay discounting, and reward/punishment-based decision-
making skills and represent the cognitive processes that regulate 
impulse control (54, 63–65). The delay discounting describes 
the tendency to discount the value of a reward as a function 
of the length of delay to its delivery. Higher delay discounting 
rates have been associated with cigarette smoking. Thus, current 
smokers tended to discount future monetary reinforcers more 
than ex-smokers and non-smokers (66), suggesting that smoking 
increases cognitive impulsivity in this task and that this effect 
is reversible. Another study confirmed the increased delay dis-
counting in smokers but found no differences in discounting rates 
for either money or cigarettes between light and heavy smokers 
(67), a result confirmed in a recent report (68).
Interestingly, performances in delay discounting at age 10 
were shown to predict the initiation of smoking behavior in 
adolescents at age 14 (12). Also, delay-discounting rate has been 
identified as a strong prognostic indicator of smoking relapse 
(13), suggesting that cognitive impulsivity can be a risk factor 
for subsequent tobacco smoking. Trait impulsivity has also 
been positively associated with the subjective rewarding effects 
of nicotine (14) as well as explicit expectancies about nicotine 
reward (16). A longitudinal study using a sample of college men 
and women showed that trait impulsivity predicts subsequent 
smoking initiation (17).
Novelty or sensation seeking can be defined as a heritable ten-
dency to seek out varied, novel, complex, and intense sensations 
and emotional experiences and to show enhanced behavioral 
responses to novel situations (69–73). It is one of the most critical 
individual difference factors predicting drug use among humans 
(74, 75). Novelty seeking is typically measured in humans by 
using questionnaires such as the Tridimensional Personality 
Questionnaire (76), the Zuckerman Sensation Seeking Scale, 
or the Cloninger’s Temperament and Character Inventory (77). 
This personality trait was shown to predict tobacco use during 
adolescence (75, 78) and the early onset of smoking in adoles-
cents (79, 80). In line with this, a study of longitudinal smoking 
patterns in adolescents found that individuals with high novelty 
seeking were significantly more likely to become regular smok-
ers than never smokers (18). In addition, novelty seeking was 
increased in heavy smokers (81) and was positively associated 
with sensitivity to the initial reinforcing effect of acute nicotine 
under controlled laboratory conditions (14, 82). A longitudinal 
study also showed that sensation seeking in college men and 
women predicts the initiation of smoking and its continuation 
20  years later (17). Finally, high levels of novelty seeking have 
been negatively correlated with smoking-cessation success, with 
reduced odds of cessation compliance and outcomes (19, 20).
Thus, novelty seeking seems to predict tobacco addiction, 
but more studies are needed in order to determine the effect of 
tobacco exposure on this personality trait.
One should nevertheless bear in mind that, although the 
association between some personality traits and drug addiction 
is frequently observed, there are no structured and established 
pre-addictive personalities. Some dissociable personality profiles, 
including impulsiveness and novelty seeking, may rather be con-
sidered as vulnerability factors and facilitate some aspects of the 
addiction process.
Attention-Deficit Hyperactivity Disorder 
and Tobacco Smoking
Attention-deficit hyperactivity disorder is a developmental 
disorder characterized by hyperactivity, high impulsivity, 
and an inability to sustain directed attention (83). ADHD 
affects approximately 6.5–8.4% of children and between 1.9 
and 6% of adults (84–86). Evidence suggests that ADHD is 
a predisposition factor for tobacco smoking. For example, 
ADHD predicted future smoking (21) and adolescents with 
ADHD were more likely to experiment with cigarettes and 
become smokers (22). In addition, ADHD symptoms during 
childhood, particularly hyperactivity/impulsivity, predicted 
later nicotine dependence in adulthood (87). ADHD status in 
childhood was also shown to predict time to relapse to smoking 
after controlling for gender, history of depression, and baseline 
smoking variables (23). Smokers with ADHD present an earlier 
onset of regular smoking, have a higher frequency of smoking 
behavior, show greater withdrawal symptoms, are more willing 
to work harder for cigarette puffs, and exhibit a higher level 
of nicotine dependence than smokers without ADHD (24–29, 
88, 89). In addition, there is an increase of ADHD symptoms 
during periods of abstinence in smokers that was associated 
with an increased risk of relapse (90). This suggests that the 
increased withdrawal symptoms observed in ADHD patients 
negatively affect the success of quitting tobacco smoking. Since 
ADHD is a neurodevelopmental disorder, there are no data 
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on the influence of tobacco smoking on the emergence of 
ADHD. However, smoking during pregnancy has previously 
been strongly associated with the risk of ADHD in offspring 
(91–95) suggesting a direct causality. However, these studies 
did not rule out the potential influence of unmeasured familial 
factors (96, 97), and the association no longer holds in recent 
studies that used different designs accounting for these factors 
(97–99). This suggests that maternal smoking during pregnancy 
reflects a genetic predisposition rather than a causal risk fac-
tor for ADHD in offspring. Individuals with ADHD may also 
be more susceptible to the negative effects of smoking. Thus, 
smokers exhibited a greater increase in attention deficits over 
the years than their never-smoking twins (100), suggesting that 
smoking can worsen attention problems.
In conclusion, there is a complex relationship between ADHD 
and smoking with ADHD contributing to smoking, but smoking 
may also contribute to the development of attention deficits.
Depression and Tobacco Smoking
Depression is characterized by depressed mood, anhedonia, 
vegetative symptoms, and impaired psychosocial functioning. 
Cigarette smoking and depression both account for significant 
morbidity, mortality, and economic burden. Depression is 
overrepresented among adult smokers and contributes to lower 
smoking-cessation rates and cigarette smoking is overrepresented 
in adult smokers prone to depression (101, 102). Longitudinal 
studies are useful to determine if depressive states can influence 
tobacco smoking. Thus, a 21-year longitudinal study found an 
association between major depression (MD) and smoking, with a 
19% increase in the average daily smoking rate and a 75% increase 
in the odds of being nicotine dependent from mid-adolescence 
to young adulthood (30) in people with MD episode. In addition, 
adolescents with a history of MD had 50% more risk to progress 
to daily smoking and were significantly less likely to quit by age 25 
compared with controls (31). These results suggest a strong influ-
ence of MD on the likelihood to develop tobacco addiction, but 
several studies suggested that less severe depressive symptoms are 
also a risk factor for tobacco dependence. For example, depression 
symptoms at mid-adolescence predicted smoking progression 
across mid-to-late adolescence (103). Adolescents with higher 
depressive symptoms were more likely to start smoking (34) and 
to progress to regular smoking compared with adolescents with 
lower depressive symptoms (35–37). Another longitudinal study 
found that depressive symptoms in early adolescence predict 
faster increases in smoking behavior (104).
In addition, depression seems to have a negative influence 
on smoking cessation since history of MD reduced the odds of 
short- and long-term smoking abstinence (32, 33). An increase 
in negative mood in the early stages of treatment for tobacco 
dependence was predictive of failure to quit smoking or smoking 
relapse (105, 106).
These data clearly indicate that depression is a risk factor for 
tobacco addiction, but other studies also support the opposite, 
i.e., that smoking influences the development of depression. Thus, 
cigarette smoking during adolescence was shown to predict the 
development of depressive symptoms (107–111) and an increased 
time of smoking dependency has been correlated with increased 
risk of depression. This suggests that the vulnerability for depres-
sion increases with higher rates of smoking (110).
In addition, quitting smoking has been associated with a sig-
nificant decrease in depression compared with continued smok-
ing (112), supporting the hypothesis that smoking might be the 
cause for mental health problems and not necessarily the inverse.
In conclusion, despite the fact that some of these studies 
failed to identify a reciprocal relationship between tobacco 
addiction and depression (30, 37, 108), the relationship seems 
to be bidirectional (113). As described earlier, tobacco depend-
ence predicts the development of depressive symptoms and MD, 
while a history of MD predicts the onset of daily smoking and 
progression to tobacco dependence. This conclusion is supported 
by a meta-analysis of 15 longitudinal studies in adolescents that 
reported evidence for a bidirectional relationship, with a larger 
effect of depression status on smoking likelihood than the effect 
of smoking on depression (114).
Anxiety Disorders and Tobacco Smoking
Anxiety disorders, such as panic disorders, phobias, generalized 
anxiety disorder, and posttraumatic stress disorder (PTSD), are 
among the most common mental disorders (115, 116). A strong 
relationship between anxiety disorders and tobacco smoking 
has been established in humans. Indeed, while tobacco smoking 
rates significantly declined from 2004 to 2011 in people without 
psychiatric illness, this is not the case in people with anxiety 
disorders (117). Along this line, patients with anxiety disorders 
had significantly higher smoking rates than a control population 
(38, 39), and anxiety disorders were significantly more prevalent 
in people diagnosed with nicotine dependence than in a non-
dependent population (118). In addition, patients with social 
anxiety or generalized anxiety disorders exhibited more severe 
nicotine dependence at baseline and smokers with a lifetime his-
tory of anxiety disorder were resistant to pharmacotherapy for 
abstinence (40).
PTSD is one of the most common anxiety disorders that can 
develop in humans after an exposure to one or more traumatic 
events, with a lifetime prevalence of approximately 8% in the 
general population (119). Smoking initiation and daily smoking 
rates were shown to increase after trauma (120, 121), and the 
presence of PTSD symptoms, such as hyperarousal and emotional 
numbing, is a predictor of tobacco dependence (43–46). Taken 
together, these data suggest that anxiety disorders are risk factors 
for the development of tobacco addiction, but prior smoking has 
also been found to be associated with increased risk to develop 
PTSD after a trauma or panic disorder (122, 123). In addition, 
smoking or smoke exposure in early life increased the likelihood 
of developing an anxiety disorder later in life (124, 125).
Finally, anxiety disorders have also been associated with 
greater difficulties for quitting tobacco smoking since smokers 
with lifetime anxiety disorder have significantly lower rates of 
abstinence and report more severe withdrawal symptoms than 
control smokers (41, 42, 126, 127). PTSD patients also exhibited 
lower rates of quitting, shorter times to first smoking relapse after 
quitting (38, 47, 48) and experienced worsened nicotine with-
drawal symptoms compared with a non-PTSD population (49). 
However, as for depression, anxiety and stress were shown to be 
TAble 2 | effects of nicotine administration on mental disorder-related 
processes in clinical studies.
Mental 
disorder
Nicotine treatment Outcome Reference
Tobacco 
addiction
Transdermal patch (21 
or 35 mg)
↗ attention Lawrence et al. (140), 
Hong et al. (141)
Nasal spray (1 mg) ↗ attention Warbrick et al. (142)
Nasal spray (1 mg) ↗ prospective 
memory
Rusted and Trawley 
(143)
Gum (4 mg) ↗ prospective 
memory
Jansari et al. (144)
Schizophrenia Transdermal patch 
(14, 21, or 35 mg)
↗ attention Barr et al. (145), 
Hong et al. (141)
Nasal spray (1 mg) ↗ PPI Hong et al. (146)
Subcutaneous 
injection (12 μg/kg)
↗ PPI Postma et al. (147)
ADHD Transdermal patch 
7 mg/kg (non-
smokers) or  
21 mg/kg (smokers)
↘ ADHD 
symptoms
Conners et al. (148), 
Levin et al. (149), 
Bekker et al. (150)
Transdermal patch 
(7 mg)
↘ motor 
impulsivity
Potter and Newhouse 
(151, 152), Potter 
et al. (153)
Major 
depression
Transdermal patch 
(17.5 mg)
↘ depression 
symptoms
Salin-Pascual et al. 
(154)
OCD Transdermal patch 
(17.5 mg)
↘ compulsion 
and anxiety
Salin-Pascual and 
Basanez-Villa (155)
PPI, prepulse inhibition of startle reflex; ADHD, attention-deficit hyperactivity disorder; 
OCD, obsessive–compulsive disorder.
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decreased in abstinent subjects by follow-up studies (112). This 
suggests that the assumption of beneficial effects of nicotine on 
anxiety and mood, which probably contributes to the mainte-
nance of smoking in populations with mental health problems, 
should be more drastically challenged to motivate quitting.
Thus, the relationship between anxiety disorders and tobacco 
addiction is probably bidirectional, a conclusion supported by 
several additional studies (120, 128–130).
Schizophrenia and Tobacco Smoking
Schizophrenia is a chronic disabling disorder characterized by 
positive symptoms (hallucinations and delusions), negative 
symptoms (blunted affect, alogia, reduced sociability, and anhe-
donia), and persistent cognitive deficits (memory, concentration, 
and learning). It affects approximately 1% of the population 
(131). Cigarette smoking is highly prevalent in persons with 
schizophrenia and schizoaffective disorder since it ranges from 
45 to 88%, compared with <20% in the general population (132). 
Individuals with schizophrenia smoke more cigarettes per day, 
are more nicotine dependent, and also have more difficulties in 
quitting smoking than smokers with no history of mental health 
problems (38), leading to high mortality due to tobacco-related 
illnesses (39). Interestingly, smokers with schizophrenia have 
higher plasma and urine levels of nicotine, even when matched 
for the number of cigarettes smoked per day and other indices 
of nicotine dependence (133–135). This is not due to a differ-
ence in nicotine metabolism (136) but rather to the manner in 
which cigarettes are smoked by schizophrenic patients. Indeed, 
schizophrenic patients take significantly more puffs, have shorter 
inter puff intervals, and larger total cigarette puff volumes com-
pared with matched healthy control smokers (137). Smokers with 
schizophrenia also exhibited a higher intensity of demand and 
greater consumption and expenditure in a cigarette purchase 
task, suggesting a higher incentive value of cigarettes in smokers 
with schizophrenia (138).
Thus, schizophrenia appears to be a strong risk factor for 
tobacco addiction, and individuals with schizophrenia may sus-
tain smoking because of its higher reinforcing effect and to remedy 
certain symptoms of the disorder (139). Further research is now 
needed to look at the alternative possibility that tobacco smoking 
may confer vulnerability to the development of schizophrenia.
eFFeCTS OF NiCOTiNe ON COGNiTiON, 
PeRSONAliTY TRAiTS, AND 
PSYCHiATRiC DiSORDeRS iN HUMANS
As described in the first part of this review, several clinical studies 
have linked tobacco addiction with impulsivity, novelty seeking, 
attention, mood disorders, ADHD, and schizophrenia. But, an 
investigation of the effects of nicotine on these personality traits 
and psychiatric disorder-associated phenotypes is important to 
better understand these relationships (see Table 2).
Cognition
In addition to its abuse liability, nicotine can also enhance 
cognitive functions, including attention and memory (156). 
Thus, nicotine and other nAChR ligands have been proposed 
as potential therapeutics for the treatment of cognitive deficits 
in pathologies, such as schizophrenia, ADHD, and Alzheimer’s 
disease (157, 158). However, chronic cigarette smoking has also 
been associated with decreased cognitive performance in mid-
dle age (159, 160) and increased risk for cognitive decline and 
dementia later in life (161).
Few studies have investigated the impact of nicotine on atten-
tion in humans. For example, transdermal nicotine improved the 
performance in a rapid visual information-processing task (140, 
141) and nicotine exposure trough nasal spray decreased the reac-
tion times in a visual oddball task in smokers (142), suggesting 
an increase in sustained attention induced by acute nicotine in 
smokers. Transdermal nicotine also significantly improved atten-
tion in both schizophrenic patients and controls (145) and visual 
attentional performance in mildly deprived smokers (162, 163). 
These studies clearly indicate that nicotine has a pro-attentional 
effect in humans. Along this line, there is evidence to suggest 
that nicotine may be useful in treating the symptoms of ADHD. 
Thus, positive effects of nicotine have been reported on attention, 
concentration, and other ADHD symptoms among adults with 
ADHD (22, 148, 149, 164, 165), indicating that ADHD patients 
may smoke as a form of self-medication.
Some studies further suggest a promnesic effect of smoking. 
Thus, abstinent smokers exhibited more impairment in visuospa-
tial working memory (VSWM) compared with current smokers 
(166), and overnight smoking abstinence in schizophrenic 
patients’ impaired VSWM performance, an effect reversed by 
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reinstatement of cigarette smoking. The effect of smoking rein-
statement was blocked by the non-selective nAChR antagonist 
mecamylamine (167), indicating that the procognitive effect of 
tobacco smoking in VSWM tasks is through nAChR activation 
in patients with schizophrenia. Nicotine administration via gum, 
patch, or injection also improved short-term memory recall in 
non-smokers (168–170). Interestingly, the effect of nicotine on 
memory seems to be dependent on baseline performance. Thus, 
Niemegeers et al. showed that the effect of subchronic nicotine 
(1 or 2 mg trough oromucosal spray three times daily for 3 days) 
was dependent on baseline performance in working and visual 
memory in young and elderly healthy subjects (171). Subjects 
with lower baseline performance benefited from nicotine 
administration, while subjects with higher baseline performance 
performed worse after nicotine administration. This suggests that 
subjects with lower cognitive performance, irrespective of age, 
may benefit from nicotine.
There have been few publications on the effect of nicotine on 
executive functions, and it is difficult to draw conclusions due 
to the heterogeneity of the procedures and results. For example, 
nicotine (1  mg through nasal spray) improved prospective 
memory in minimally deprived (2 h) smokers and non-smokers 
when the subjects were able to devote resources to that task, but 
impaired the performance when they completed a concurrent 
auditory monitoring task (143). Nicotine (2 mg gum) has been 
shown to improve performance in complex flight simulation 
tasks, which involve high cognitive load, in non-smoking pilots, 
but had no effect on the executive function aspect of attention in 
never smokers (2 and 4 mg gums) (172).
In a study investigating the effect of nicotine on the perfor-
mance of male non-smokers with high or low attentiveness on the 
Wisconsin Card Sorting Test (WCST), nicotine administration 
(7 mg patch) in the high attentiveness group impaired the per-
formance (173). This suggests a deleterious effect of nicotine on 
strategic planning, set-shifting, and mental flexibility in this sub-
population. Finally, in a study using a virtual reality paradigm 
that assesses multiple cognitive constructs simultaneously (144), 
nicotine improved the overall performance, time-based prospec-
tive memory, and event-based prospective memory in minimally 
(2 h) deprived smokers (4 mg nicotine gum), but not in never 
smokers (2  mg nicotine gum). At the same time, action-based 
prospective memory was enhanced in both groups.
Thus, nicotine seems capable to improve, impair, or have no 
effect on executive functions depending on the task, the dose of 
nicotine or the target population, highlighting the need for new 
studies to obtain a clearer picture on that issue.
Several studies show that cigarette smoking impairs decision-
making processes assessed through different neurocognitive tasks 
(174–177). However, these studies do not discriminate the effects 
of nicotine alone from the effects other psychoactive compounds 
found in tobacco smoke. Further studies are needed for providing 
clear information about the consequences of chronic nicotine 
exposure on decision-making.
Deficits in pre-attentive sensory information processing, 
characterized by the inability to filter out or gate sensory 
information, are thought to contribute to the higher order 
cognitive deficits observed in schizophrenia. This includes 
attention, working memory, verbal learning and memory, 
decision-making, and executive functioning (178, 179). One 
measure of sensory processing is the P50 suppression that 
measures the inhibition of electroencephalic cortical response 
to the second auditory stimulus presented 50 ms after the first. 
Patients with schizophrenia fail to suppress the response to the 
second auditory stimulus reflecting gating deficits (180). Several 
studies have shown that nicotine can improve P50 suppression. 
Thus, cigarette smoking improved P50 suppression in abstinent 
smokers with schizophrenia (181), and nicotine gum improved 
P50 suppression in non-smoking subjects with impaired gating 
or healthy controls (182–184).
Another measure of sensory information processing is the 
prepulse inhibition (PPI) of startle reflex that reflects the inhibi-
tion of a blinking reflex to a loud startling stimulus presented after 
a weak prepulse stimulus. This gating mechanism is also impaired 
in patients with schizophrenia (185) and nicotine (administered 
via nasal spray or subcutaneous injection) improved PPI in 
smokers and non-smokers with schizophrenia or in healthy 
subjects (146, 147). In addition, PPI of satiated smokers with 
schizophrenia is comparable to PPI of smokers without schizo-
phrenia (186). Taken together, these data suggest that nicotine 
can improve sensory information processing and those patients 
with schizophrenia may smoke in part to alleviate their deficit in 
sensory gating.
Very few studies have investigated the effect of nicotine on 
impulsivity in humans. A positive correlation between levels of 
nicotine exposure and discounting of delayed monetary reinforc-
ers has been observed in chronic smokers but not in ex-smokers 
(187, 188), suggesting that nicotine administration trough smok-
ing increases cognitive impulsivity, an effect that is reversible. 
However, a positive effect of nicotine on the Stop Signal Reaction 
Time measure of the Stop Signal Task has been observed in 
adolescent and young non-smoking adults with ADHD, and in a 
control population (151–153), indicating that nicotine can reduce 
motor impulsivity. Thus, nicotine appears to have a differential 
effect on these two types of impulsivity, but more studies are 
needed to conclude.
We did not find additional clinical data on the effects of nico-
tine on cognitive impulsivity or on novelty seeking, highlighting 
the need for such investigations.
Depression
Self-medication is one of the possible explanations for the impact 
of depression on cigarette smoking since nicotine reduces nega-
tive affect and can have antidepressant effects (189). This theory 
is supported by the fact that patients with MD increased their 
smoking behavior when they experienced depressive symptoms 
(190). In addition, several clinical studies reported that nicotine 
administration through transdermal patches reduced symptoms 
of depression, even in non-smoking depressed patients (154, 191) 
and relieved self-reported depression in regular smokers (150).
Interestingly, chronic administration of low levels of nicotine, 
as delivered by the nicotine patch, is thought to desensitize, rather 
than activate, nAChRs (192, 193), suggesting that the therapeutic 
effect of nicotine on depression may be mediated by inactivation 
of nAChRs. This is supported by the fact that mecamylamine, 
TAble 3 | Association between pre-existing endophenotypes and nicotine addiction-related features in animal studies.
Pre-existing phenotype Nicotine addiction-related features Species Reference
Motor impulsivity (5-CSRTT) ↗ IVSA acquisition and under PR schedule Wistar rats Diergaarde et al. (206)
Cognitive impulsivity (delayed discounting task) ↗ IVSA under PR schedule Wistar rats Diergaarde et al. (206), 
Diergaarde et al. (207)↗ resistance to extinction of nicotine-seeking after IVSA
↗ cue-induced reinstatement of nicotine seeking
Ø somatic withdrawal Lister-hooded rats Kolotroni et al. (208)
Locomotor response to novelty (horizontal 
locomotion)
↗ IVSA acquisition and under PR schedule Sprague-Dawley rats Suto et al. (209)
Ø IVSA acquisition and under PR schedule Sprague-Dawley rats Guillem et al. (210)
↘ nicotine-induced CPP C57Bl/6N mice Bernardi and Spanagel (211)
↘ nicotine-induced CPP Sprague-Dawley rats Pastor et al. (212)
↗ social anxiety in response to a nicotine challenge after 
nicotine abstinence 
Sprague-Dawley rats Aydin et al. (213–216)
Locomotor response to novelty (rearing) and 
novelty seeking (novel object preference)
Ø voluntary oral nicotine intake and nicotine-induced 
CPP
Wistar rats Pawlak and Schwarting 
(217, 218)
Novelty seeking (novel object preference) Predictive of nicotine IVSA Sprague-Dawley rats Wang et al. (219)
Novelty seeking (hole-board activity box) ↗ voluntary oral nicotine intake C57Bl/6 mice Abreu-Villaca et al. (220)
Anxiety (EPM and hole-board activity box) Ø voluntary oral nicotine intake C57Bl/6 mice Abreu-Villaca et al. (220), 
Manhaes et al. (221)
Anxiety (EPM) Ø voluntary oral nicotine intake Wistar rats Pawlak and Schwarting 
(217)
Anxiety (CPP apparatus used as a dark–light 
box)
↗ nicotine-induced CPP Sprague-Dawley rats Falco et al. (222)
Anxiety (EPM) Predictive of nicotine IVSA and context-induced 
reinstatement of nicotine seeking
Sprague-Dawley rats Wang et al. (219)
Stress reactivity (multiple tests) Ø IV SA acquisition and extinction of nicotine seeking Intercross between 
C57Bl/6J and C3H mice
Bilkei-Gorzo et al. (223)
↗ stress-induced reinstatement of nicotine seeking
Depression (tail suspension test) Predictive of nicotine IVSA and context-induced 
reinstatement of nicotine seeking
Sprague-Dawley rats Wang et al. (219)
5-CSRTT, 5-choice serial reaction time task; IVSA, intravenous self-administration; PR, progressive ratio; CPP, conditioned place preference; EPM, elevated plus maze.
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a non-selective antagonist at heteromeric nicotinic receptors, 
decreased depression-like symptoms in patients with Tourette’s 
disorder (194–197) and enhanced the effects of a selective seroto-
nin reuptake inhibitor (SSRI) in depressed subjects (198).
In conclusion, nicotine can relieve some symptoms of depres-
sion, potentially via desensitization of nAChRs thus supporting 
the self-medication hypothesis, which may nevertheless not be 
the only valid one.
Anxiety Disorders
Several studies have shown a positive association between 
symptom severity in PTSD patients and their desire to smoke 
in order to reduce negative affect (129, 199–201). Other studies 
also suggested that this association was mediated by the expec-
tancy that smoking would reduce negative affect (202) and that 
patients with PTSD smoked and relapsed to smoking in response 
to negative affect and trauma (48, 203). This suggests that peo-
ple with PTSD smoke to relieve negative affect and anxiety as 
a form of self-medication, an hypothesis supported by the fact 
that PTSD symptoms are reduced by nicotine intake (43–46) and 
by the anxiolytic effect of nicotine patches in non-smokers with 
obsessive–compulsive disorders (155). Thus, people with anxi-
ety disorders may smoke to alleviate their symptoms, but more 
clinical studies on the effect of nicotine on anxiety are needed to 
support this conclusion.
PReDiSPOSiNG eNDOPHeNOTYPeS FOR 
NiCOTiNe TAKiNG AND SeeKiNG iN 
PReCliNiCAl STUDieS
Some psychological constructs, in particular, have been repeat-
edly associated with vulnerability to addiction, e.g., sensation 
seeking, impulsivity, and anxiety (6, 7, 204, 205). To date, the 
majority of preclinical animal research on individual differences 
in the response to drugs of abuse has mostly focused on cocaine. 
Additional work is now needed for nicotine, although some inter-
esting data have nevertheless been generated as detailed in the 
following paragraphs (see Table 3). In this review, we will strictly 
focus on behaviors reflecting processes that directly contribute to 
the addiction cycle, such as those related to (i) drug rewarding 
properties (e.g., conditioned place preference (CPP), acquisition 
of self-administration), (ii) later stages of self-administration 
(e.g., increasing fixed ratios), (iii) motivation for the drug (e.g., 
progressive ratio schedules of reinforcement), (iv) persistence of 
drug seeking (e.g., extinction of self-administration), (v) relapse, 
and (vi) withdrawal syndrome during abstinence.
impulsivity
High impulsivity has been associated with a wide range of 
neuropsychiatric disorders, including ADHD (224), mood dis-
orders (225), and also drug addiction (64, 226, 227). Findings in 
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trait-impulsive laboratory animals suggest that high impulsivity 
represents a vulnerability factor for addiction to several classes of 
drugs including cocaine (228–230), alcohol (231), and nicotine 
(53, 206). One plausible hypothesis is that high impulsivity results 
from a dysfunction of the frontal cortex and that this pre-existing 
dysfunction may facilitate the progressive incapacity of the frontal 
cortex to suppress maladaptive responses that develop following 
repeated exposure to a drug (232). Alternatively, drug intake may 
normalize excessive impulsivity in some individuals and may 
therefore represent a form of self-medication (53). As described 
earlier, impulsivity encompasses a complex array of behavioral 
processes, which can be categorized through at least two major 
components: motor/action impulsivity (motor disinhibition) 
and cognitive/choice impulsivity (impulsive decision-making). 
Several procedures have been developed to provide objective 
measures of impulsivity in animals, including delay-discounting 
tasks and the 5-choice serial reaction time task, an analog of the 
human continuous performance task (233, 234).
Very few preclinical studies have examined the putative link 
between pre-existing manifestations of impulsivity and nicotine 
addiction-like behaviors. Yet, one comprehensive study has shown 
that poor impulse control influences the motivational properties 
of nicotine and of nicotine-associated cues on a self-administra-
tion procedure in rats, and that sub-dimensions of impulsivity 
predict vulnerability to distinct stages of nicotine-seeking 
behavior (206). The authors found that high motor impulsivity on 
a 5-choice serial reaction time task predicts both enhanced self-
administration of nicotine during the acquisition and increased 
motivation for nicotine under progressive ratio of reinforcement. 
At the same time, high choice impulsivity on a delayed reward 
task was mostly predictive of both increased resistance to extinc-
tion of nicotine-seeking and increased cue-induced relapse of 
nicotine seeking after extinction. High-impulsive choice was 
also associated with higher motivation for nicotine when ratios 
of response requirement are increased, an observation that was 
confirmed by these authors in the second study (207). In contrast, 
high- and low-impulsive rats selected on a delay discounting task 
appear to show similar somatic withdrawal syndrome intensity 
after chronic exposure to low dose of nicotine (208). These data 
suggest that the two sub-dimensions of impulsivity influence 
both distinct and overlapping processes through the dynamics of 
addiction development in vulnerable individuals.
Response to Novelty
The second behavioral factor strongly linked to addiction includ-
ing smoking is the novelty/sensation seeking trait (7, 205, 235). 
Like impulsivity, novelty/sensation seeking represents a multifac-
eted behavioral construct and can be divided into a number of 
dimensions. Several tasks have been developed in animal models 
to assess responses to novelty.
The primary animal model of sensation seeking is measured 
as an enhanced locomotor activity in a novel and inescapable 
environment (236, 237). As for impulsivity, only a small number 
of preclinical studies have examined the relationship between 
pre-existing high locomotor response to novelty and nicotine 
addiction-like behaviors. Consistent with what was reported 
for other psychostimulants (237), one study found that high 
locomotor responding to a novel environment predicted the 
propensity to self-administer nicotine under both fixed and 
progressive ratios of reinforcement in rats (209). However, such 
an association was not observed in a more recent study where 
rats screened as high and low responders to novelty displayed 
similar levels of nicotine self-administration, although high 
responders were more prone to self-administer nicotine when it 
was delivered concomitantly with IMAOs (210). In contrast, a 
study reported that mice showing low basal locomotor activity 
manifested nicotine-induced CPP, while mice exhibiting high 
basal locomotor activity did not (211). However, in this study, 
the mice had previously been exposed to nicotine for prior 
experimental testing, which might have influenced subsequent 
nicotine rewarding effects (238). Consistently, other authors 
showed that rats classified as low responders according to their 
locomotor response to novelty following an injection of nicotine, 
showed nicotine-induced CPP after a long- but not short-term 
conditioning procedure, while rats classified as high responders 
did not show CPP under any condition (212). Also, rats selected 
as high locomotor responders to novelty showed enhanced social 
anxiety-like behavior during abstinence after repeated nicotine 
exposure (213–216).
In addition to the sensation seeking trait that is modeled as 
high locomotor reactivity to novel environments, novelty seeking 
has been proposed to reflect a distinct dimension of sensation 
seeking that would differentially contribute to the vulnerability 
to develop addiction (239, 240). The terms sensation seeking and 
novelty seeking are often used in an exchangeable way throughout 
the literature, though. In animal studies, novelty seeking per se is 
modeled by a high propensity to visit a novel object or environ-
ment in a free choice procedure, the so-called novelty preference. 
Very few studies have attempted to identify the predictive value 
of novelty seeking to the appetence for nicotine. Interestingly, 
it has been shown that rats, screened as high novelty seekers as 
measured by their preference for a novel object in a procedure 
where they could freely explore either a novel or a familiar 
object, were also characterized as high locomotor responders to 
novelty as measured by the number of rears they displayed in 
an open-field (217). However, high novelty seeker rats did not 
show differences compared with rats screened as low novelty 
seekers when subsequently tested for oral nicotine consumption. 
In another study, the same authors also observed no enhanced 
nicotine-induced CPP in rats with high rearing activity, although 
it is difficult to conclude since they did not observe nicotine CPP 
in any of the rat subpopulations tested in this study (218). Using 
multiple regression analysis, other authors reported that novelty 
seeking measured as exploration of a novel object predicted 
nicotine self-administration in female, but not in male, rats (219). 
Another animal model of novelty seeking based on the number of 
head-dips in the hole-board apparatus has been used (241). Mice 
preselected for high novelty seeking in this test showed a marked 
increase for oral nicotine intake over time, while mice with low 
novelty seeking did not (220). However, mice showing high head-
dip behavior in the hole-board task and that had been exposed 
to nicotine during gestation and suckling tended to consume less 
nicotine when tested during adolescence (242). In contrast, the 
same study showed that mice similarly exposed to nicotine and 
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showing high rearing or high general locomotor behavior in the 
hole-board displayed increased oral nicotine intake.
Taken together, these data suggest that additional work 
is clearly needed to conclusively acknowledge whether high 
response to novelty/high novelty seeking represents a significant 
risk factor for nicotine addiction and, if so, for which specific 
features of this disorder. Novelty seeking measured as high nov-
elty preference, but not high novelty-induced locomotor activity, 
has notably been shown to predict the compulsive use of cocaine 
in rats, a hallmark feature of addiction (243). The existence of a 
similar causal association has not been investigated for nicotine, 
partly because behaviors reflecting loss of control over nicotine 
intake and compulsive nicotine taking and seeking have not been 
accurately modeled so far. The recent development of increas-
ingly reliable models may open new paths for such longitudinal 
investigations (244–247).
Anxiety and Mood Disorders
There is a high prevalence of tobacco smoking in subjects with 
mood or anxiety disorders (235, 248–250). It has been proposed 
that individuals may use drugs including nicotine as a coping 
strategy to self-regulate affective distress states (251–253). Drug 
users may self-medicate for affective distress existing before the 
initiation of drug use and also to alleviate mood and anxiety 
distress that are part of the withdrawal syndrome resulting from 
abstinence (254). Alternative explanations for the strong associa-
tion between smoking and mood and anxiety disorders are also to 
be considered, notably since repeated use of nicotine significantly 
impacts anxiety and mood processing. Below, we review the pre-
clinical studies that assessed whether the manifestation of such 
disorders beforehand may predict the future response to nicotine.
In preclinical studies, anxiety is usually assessed using pro-
cedures that exploit the emotional conflict occurring between 
the innate strong tendency to explore novel environments 
and the natural fear of open and/or brightly lit spaces. In particu-
lar, the elevated plus maze (EPM) is commonly used with anxiety 
measured as the preference of animals for closed versus open arms 
(255). High anxiety in this task predicts several features of cocaine 
and alcohol, but not heroin, addiction (7). Adolescent mice with 
high anxiety in this test showed similar levels of oral nicotine 
intake as mice with low anxiety in a free choice procedure (221). 
However, during a withdrawal period after 2 weeks of exposure 
to nicotine through their drinking bottles, adolescent mice with 
high anxiety consumed less nicotine than mice with low anxiety 
when tested in a free choice procedure (221). The same group 
further showed no differences in oral consumption of nicotine 
in a free choice procedure between adolescent mice with high 
and low anxiety classified according to their percentage of center 
squares crossed in a hole-board activity box (220). Another study 
also reported no association between prior behavioral measure-
ments on the EPM and oral nicotine consumption in rats (217). In 
contrast, a study in adolescent rats reported that individuals with 
high anxiety measured as the time spent in the white versus the 
black chamber of a biased CPP apparatus manifested subsequent 
nicotine-induced CPP while individuals with low anxiety did not 
(222). Furthermore, in a comprehensive study assessing several 
risk factors for nicotine self-administration in a social context in 
rats, multiple regression analysis found that anxiety measures on 
the EPM were a predictor of nicotine intake in males, but not in 
females, while measures of depression on the tail suspension test 
were predictors of nicotine intake in both males and females (219). 
In males, both depression- and anxiety-related measures also 
predicted context-induced nicotine reinstatement. Interestingly, 
mice generated from the intercross of high (C57BL/6J) and low 
(C3H/J) emotional mouse strains and classified as “high stress 
reactive” according to their scores in an elevated zero maze, light–
dark box, startle response, and forced swim tests, showed higher 
vulnerability to relapse but not to initiation or maintenance of 
nicotine self-administration compared with low and average 
stress reactive animals (223).
In addition to data regarding the causal link between inter-
individual differences in anxiety- and depression-like behaviors 
and appetence for nicotine, it was demonstrated that acute 
stressor exposure through a single episode of intermittent foot-
shock administered 24 h before the start of place conditioning 
dose-dependently facilitated acquisition of CPP to nicotine 
in adolescent rats (256). Prenatal stress in rats also increased 
nicotine reinforcing properties in a CPP procedure and anxi-
ety withdrawal symptom at the cessation of nicotine exposure 
(257, 258). Finally, chronic mild stress, considered as a model of 
depression, which was delivered prior to nicotine exposure was 
found to exacerbate nicotine withdrawal syndrome in rats (259).
Although these data are heterogeneous, they suggest that anxi-
ety and mood disorders may represent a significant predictor of 
nicotine addiction and may notably influence the vulnerability 
to relapse after abstinence, depending on the sex and the age of 
the individual.
Cognitive impairments
In addition to alleviating stress, anxiety, and improving mood, 
nicotine has the ability to enhance cognition. Nicotine use has 
also been proposed as a self-treatment for cognitive deficits 
that are encountered in numerous psychiatric diseases strongly 
represented in smoker populations such as schizophrenia or 
ADHD (260). As for other aspects of the comorbidity between 
smoking and psychiatric conditions, one fundamental pending 
question is whether cognitive deficits are of premorbid origin 
or develop after long-term exposure to nicotine and subsequent 
withdrawal. Animal models have proven to be useful tools for 
helping to resolve these issues with the possibility for well-
controlled longitudinal studies to be conducted. Nevertheless, 
while many studies have looked at the effects of nicotine on 
cognitive processes, there is a great lack of preclinical studies 
investigating the relationship between inter-individual differ-
ences in cognitive functions, such as baseline impairments in 
attention, learning, and memory functions, and addiction-like 
behaviors, especially with regard to nicotine. One study pro-
vided evidence for a causal link between prior cognitive deficits 
and behavioral response to nicotine, by looking at individual 
differences in baseline PPI of acoustic startle reflex and subse-
quent nicotine-induced locomotor effects including locomotor 
sensitization. Disruption in the PPI is a model of cognitive 
impairment in schizophrenia and reveals deficits in the senso-
rimotor gating system which is critical for the integration of 
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sensory and cognitive information processing and execution of 
appropriate motor responses. The authors showed that the acute 
effect of nicotine on locomotion was higher in rats classified as 
high-inhibitory, while a locomotor sensitization after repeated 
exposure to nicotine developed only in low-inhibitory rats (261). 
Another study reported that neonatal ventral hippocampal 
lesions that produced post-adolescent onset, pharmacological, 
neurobiological, and cognitive features of schizophrenia, such 
as spatial learning and working memory deficits, increased nico-
tine self-administration and nicotine seeking during extinction 
in adult rats (262). Furthermore, spontaneously hypertensive 
rats, considered as the most valid animal model of ADHD 
and that display symptoms of inattentiveness, impulsivity, and 
hyperactivity, show enhanced nicotine self-administration 
(263) and CPP (264). It has also been shown that social interac-
tion phenotypes are predictor of nicotine self-administration 
and nicotine seeking in rats, although it is difficult to conclude 
about which cognitive functions – if any – were implicated in 
such a causal association (219).
Taken together, these data suggest that different behavioral 
factors may preferentially contribute to some of the many dimen-
sions of the addiction cycle. Combinations of some predisposing 
behavioral traits may result in specific vulnerability profiles 
predicting higher risk for starting nicotine use or shifting toward 
nicotine abuse, or for relapse during abstinence. For instance, 
outbred rats classified as high locomotor responders to novelty 
show decreased anxiety as compared with low responders (265). 
Also, as mentioned earlier, a study based on a dimensional 
analysis approach within a single and large population of rats 
reported that high locomotor reactivity to novelty predicts the 
propensity to self-administer cocaine, while high novelty seek-
ing in a free choice procedure predicts the transition to com-
pulsive cocaine seeking (243). Additional studies measuring the 
inter-individual vulnerability for different personality traits and 
addiction-like phenotypes in the same population of animals 
may significantly improve our understanding of vulnerability to 
nicotine addiction.
eFFeCTS OF NiCOTiNe ON COGNiTive 
AND AFFeCTive eNDOPHeNOTYPeS iN 
PReCliNiCAl STUDieS
impulsivity
In addition to a possible influence of pre-existing impulsivity on 
later development of drug abuse, psychostimulant abuse may 
itself lead to the increased impulsivity often observed in chronic 
drug abusers, including nicotine, and, thereby, help to develop 
and maintain addiction (see Table 4) (348).
Animal studies on the effects of nicotine on inhibitory control 
have mostly focused on motor impulsivity using attentional 
tasks. Acute nicotine exposure consistently increased premature 
responding on serial reaction time- (266–272) and go/no-go-tasks 
in rats (273). These effects appear to be long-lasting, although 
data about chronic exposure to nicotine on motor impulsivity are 
fewer and less consistent (268, 271, 274, 276). One recent study 
in mice demonstrated that chronic oral, but not acute, injections 
of nicotine attenuated phencyclidine-induced increases in motor 
impulsivity (349). Increased motor impulsivity was further 
reported in rats after prenatal exposure to nicotine, while cogni-
tive impulsivity was not affected (350, 351). In adolescent, but 
not post-adolescent rats, repeated exposure to nicotine increased 
impulsive action but not impulsive choice (275).
Few animal studies have focused on the consequences of nico-
tine exposure on cognitive impulsivity using delay-discounting 
tasks, and the data are more heterogeneous. Acute injections of 
nicotine dose-dependently increased impulsive choice in rats, 
while repeated injections of nicotine also increased impulsive 
choice, but to the same extent regardless of the dose (277). 
After nicotine treatment cessation, impulsive choice remained 
enhanced for a long period before gradually returning to base-
line, suggesting that chronic nicotine exposure can produce 
long-lasting although reversible alterations in inhibitory control. 
Acute exposure to nicotine increased both impulsive action in 
a go/no go task and impulsive choice in a delayed reward task 
in rats, with greater sensitivity of impulsive choice to nicotine 
(273). Both acute and subchronic injections of nicotine increased 
impulsive choice in rats in a procedure where the delayed reward 
was made preferable by decreasing the probability rather than 
the magnitude of the immediate reward (278). In contrast, a 
study reported decreased impulsive choice in rats after acute 
nicotine, and this effect was abolished after repeated nicotine 
injections (279). Finally, in rats with high cognitive impulsivity, 
chronic nicotine exposure and nicotine withdrawal had no effect 
on impulsive choice, while chronic nicotine exposure increased 
impulsive choice in low-impulsive rats, with no effects on animals 
with intermediate impulsivity levels (352). Nicotine may result in 
varying effects on choice processing, depending on key param-
eters such as basal levels of impulsivity, reinforcement amount, or 
delay (e.g., adjusting versus fixed delay), and genetic background 
of rats.
Anxiety and Mood Disorders
The effects of acute nicotine exposure on anxiety-like behavior 
is highly dependent on the task, dose, timing of testing, sex, 
strain, age, and basal anxiety levels of the animals (353, 354). 
In the EPM, acute or subchronic systemic nicotine was found 
anxiolytic in some studies (280, 285, 293), anxiogenic at both 
low and high doses in others (288, 289, 292, 294), or to have no 
effects (288), in rats. Inconclusive data have also been obtained in 
mice, with anxiolytic effects at low doses and anxiogenic effects at 
high doses of nicotine in C57BL/6J, CD1, and BALB/C mice (283, 
284, 286, 287), and anxiogenic effects with an intermediate dose 
with anxiolytic action when given subchronically in Swiss mice 
(290, 291). In the social interaction test, it is also generally found 
that low doses of nicotine induce anxiolytic effects, while high 
doses are anxiogenic (281). However, a study reported that acute 
nicotine injections performed 5 min before testing induced anxi-
ogenic effects, whereas nicotine injections using the same dose 
but performed 30 min before the task elicited anxiolytic effects 
(282). Nicotine reduced stress-induced hyperthermia (355).
Interestingly, a tolerance to nicotine’s effects on anxiety may 
develop over time. Chronic exposure to nicotine was found to 
have no longer effects on anxiety or to induce anxiolytic effects 
TAble 4 | effects of nicotine administration on affective and cognitive processes in animal studies.
Phenotype Nicotine 
treatment
Outcome Species Reference
Motor impulsivity (serial reaction time-; go/no go-; 
stop-signal-; and DRL-tasks)
Acute ↗ Lister-hooded rats Mirza and Stolerman (266)
Sprague-Dawley rats Stolerman et al. (267)
Wistar rats Blondel et al. (268), Bizarro et al. (269), van Gaalen 
et al. (270), Semenova et al. (271), Tsutsui-Kimura et al. 
(272), Kolokotroni et al. (273)
Chronic ↗ Sprague-Dawley rats Blondel et al. (268)
Lister-hooded rats Grottick and Higgins (274)
Wistar rats Semenova et al. (271), Counotte et al. (275), 
Kirshenbaum et al. (276)
Ø Wistar rats Counotte et al. (275)
Cognitive impulsivity (delayed discounting task) Acute ↗ Wistar rats Dallery and Locey (277)
Lister-hooded rats Kolokotroni et al. (273)
Long–Evans rats Kelsey and Niraula (278)
↘ Fischer rats Anderson and Diller (279)
Lewis rats
Chronic ↗ Long–Evans rats Dallery and Locey (277), Kelsey and Niraula (278)
Ø Wistar rats Counotte et al. (275)
Fischer rats Anderson and Diller (279)
Lewis rats
Anxiety-like behaviors (EPM; social interaction test; 
open field; dark–light box)
Acute ↘ Sprague-Dawley rats O’Neill and Brioni (280)
Lister-hooded rats File et al. (281)
CD1 mice Irvine et al. (282)
C57Bl/6 mice Balerio et al. (283, 284)
BALB/C mice Villegier et al. (285), McGranahan et al. (286),  
Varani et al. (287)
↗ Lister-hooded rats File et al. (281)
Wistar rats Ouagazzal et al. (288)
CD1 mice Irvine et al. (282)
BALB/C mice Irvine et al. (289)
Swiss mice Balerio et al. (283, 284), Biala and Kruk (290), Biala 
et al. (291), Zarrindast et al. (292), Varani et al. (287)
Ø Lister-hooded rats Ouagazzal et al. (288)
Sprague-Dawley rats Villegier et al. (285)
Chronic ↘ Wistar rats Ericson et al. (293)
Lister-hooded rats Irvine et al. (289)
Sprague-Dawley rats Elliott et al. (294)
Swiss mice Biala and Kruk (290), Biala et al. (291)
↗ Wistar rats Irvine et al. (295)
Sprague-Dawley rats Elliott et al. (294)
C57Bl/6J mice Caldarone et al. (296), Trigo et al. (297), Bura et al. 
(298)
Ø Wistar rats Besson et al. (299)
C57Bl/6J mice Ijomone et al. (300), Caldarone et al. (296)
Fear conditioning/contextual safety discrimination Acute ↗ C57Bl/6 mice Gould and Wehner (301)
BALB/C mice Gould (302)
A/J mice Gould and Higgins (303)
129/SvEv mice Gould and Lommock (304)
DBA/1J mice Wehner et al. (305)
DBA/2J mice Davis et al. (306), Davis et al. (307), Portugal et al. (308)
Ø C57Bl/6 mice Gould and Wehner (301)
C3H/HeJ mice Gould (302)
CBA/J mice Portugal et al. (308)
↘ Wistar rats Szyndler et al. (309)
C57BL/6J Kutlu et al. (310)
Chronic Ø Wistar rats Szyndler et al. (309)
C57Bl/6 mice Davis et al. (306)
BALB/C mice Portugal et al. (308)
A/J mice
129/SvEv mice
(Continued)
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Phenotype Nicotine 
treatment
Outcome Species Reference
DBA/1J mice
DBA/2J mice
C3H/HeJ mice
CBA/J mice
Depression-like behaviors (learned helplessness; 
forced swim-; and tail suspension tasks)
Acute ↘ Sprague-Dawley rats Tizabi et al. (311)
Wistar rats Vazquez-Palacios et al. (312)
Flinders sensitive line rats Suemaru et al. (313)
Fawn-hooded rats Andreasen and Redrobe (314)
C57Bl/6J mice Tizabi et al. (315)
BALB/C mice Villegier et al. (285)
Ø Sprague-Dawley rats Tizabi et al. (311)
Flinders resistant line rats Andreasen and Redrobe (314)
ACI/N rats Tizabi et al. (315)
NMRI mice Villegier et al. (285)
Chronic ↘ Wistar rats Semba et al. (316)
Flinders sensitive line rats Djuric et al. (317)
Flinders resistant line rats Tizabi et al. (311)
Fawn-hooded rats Vazquez-Palacios et al. (312)
Wistar-Kyoto rats Tizabi et al. (315), Tizabi et al. (318)
Ø Wistar rats Tizabi et al. (311)
Flinders resistant line rats Tizabi et al. (315)
ACI/N rats Tizabi et al. (318), Ijomone et al. (300)
↗ Wistar-Kyoto rats Tizabi et al. (318)
Learning and Memory (active/passive avoidance 
learning; radial-arm maze; Lashley III maze; object 
recognition task; water maze; serial pattern learning)
Acute ↗ Wistar rats Puma et al. (319)
Sprague-Dawley rats Levin et al. (320), Levin et al. (321)
Ø Sprague-Dawley rats Levin et al. (320)
NMRI mice Moragrega et al. (322)
↘ NMRI mice Moragrega et al. (322)
Chronic ↗ Sprague-Dawley rats Levin et al. (323)
Fischer rats Levin et al. (324)
CD1 mice Levin et al. (325), Arendash et al. (326), Socci et al. 
(327), Levin and Torry (328), Yilmaz et al. (329), Attaway 
et al. (330), Levin et al. (331), Ciamei et al. (332)
↘ Sprague-Dawley rats Yilmaz et al. (329)
Ø Sprague-Dawley rats Levin and Torry (328)
Fischer rats Attaway et al. (330)
NMRI mice Vicens et al. (333)
Attention (5-CSRTT; 2-choice stimulus detection task) Acute ↗ Lister-hooded rats Mirza and Stolerman (266)
Wistar rats Blondel et al. (334)
Sprague-Dawley rats Grilly (335)
Fischer × Brown 
Norway hybrid rats
Grilly et al. (336), Mirza and Bright (337), Bizarro 
and Stolerman (338), Quarta et al. (339), 
Semenova et al. (271)
Ø Wistar rats Mirza and Bright (337)
Lister-hooded rats Semenova et al. (271)
Chronic Ø Wistar rats Blondel et al. (334)
↗ Lister-hooded rats Grottick and Higgins (274)
Wistar rats Hahn and Stolerman (340), Hahn et al. (341), 
Semenova et al. (271)
Probability discounting Acute ↘ or Ø Long–Evans rats Mendez et al. (342)
Chronic 
neonatal
Ø Sprague-Dawley rats Mitchell et al. (343)
Reversal learning Chronic ↘ C57Bl/6J mice Ortega et al. (344), Cole et al. (345)
Ø C57Bl/6J mice Ortega et al. (344)
Strategy shifting Chronic Ø C57Bl/6J mice Ortega et al. (344), Cole et al. (345)
Attentional set-shifting Acute ↗ Lister-hooded rats Allison and Shoaib (346), Wood et al. (347)
Chronic ↗ Lister-hooded rats Allison and Shoaib (346)
DRL, differential reinforcement of low rate; EPM, elevated plus maze; 5-CSRTT, 5-choice serial reaction time task.
TAble 4 | Continued
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to which tolerance also develops eventually in the EPM and the 
social interaction test, in rats and mice (289–291, 293, 299, 300). 
The consequences of chronic nicotine exposure also depend on 
several factors such as sex or basal levels of anxiety. For instance, 
mice that overexpress the R isoform of acetylcholinesterase 
exhibit increased anxiety that is normalized by chronic forced 
nicotine consumption (356). Chronic nicotine treatment also 
reversed affective deficits produced by chronic mild stress (357). 
Yet, increased anxiety was also observed in the EPM and the 
light–dark box after chronic nicotine consumption (296–298). 
One study reported increased anxiety in the social interaction 
test in rats after nicotine self-administration, which may appear 
contradictory to the self-medication hypothesis (295).
Increased anxiety is consistently observed when testing is 
performed during nicotine withdrawal in the EPM, light–dark 
box, or social interaction test (221, 282, 295, 358–361) and is 
reduced by nicotine injection (289). Nicotine withdrawal also 
increased sensitivity to stressors in the light-enhanced startle 
paradigm (362).
These studies suggest that nicotine effects on anxiety are 
dependent on various factors such as the source of anxiety, base-
line levels, and genetic background of the individuals. Nicotine 
may be used to self-medicate anxiety-related distress associated 
with abstinence or in people with predisposing phenotypes, while 
it may have opposite effects on anxiety in other individuals or 
under different conditions. In the latter case, smoking behavior 
might be sustained by the belief that nicotine consumption will 
alleviate the anxiety that was essentially induced by smoking itself 
in the first place, while long-term smoking cessation would actu-
ally be much more beneficial for reversing such anxiety-related 
problems.
The effects of nicotine on fear conditioning in rodents are 
clearer than those on anxiety-like behavior (363). Studies have 
consistently reported enhanced hippocampus-dependent fear 
conditioning in mice after acute nicotine exposure (302–305, 
307), while there is no effect on hippocampus-independent fear 
conditioning or on general freezing behavior (301, 302). Acute 
nicotine was further shown to impair contextual safety discrimi-
nation in a safety learning paradigm (310). A tolerance to these 
effects seems to develop under chronic nicotine exposure in 
mice and rats, while nicotine withdrawal altered fear condition-
ing (306, 308, 309, 353, 363). Furthermore, a study showed that 
nicotine had differential effects on extinction of fear conditioning 
depending on when it was administered, during training and/or 
during extinction, and on the context during extinction (364), 
suggesting that nicotine may strengthen contextual fear memories 
and interfere with extinction. Chronic nicotine administration 
2  weeks prior to the training impaired subsequent cued – but 
enhanced contextual – fear extinction (365). Studies on fear 
conditioning extinction are particularly relevant in the context of 
the self-medication for emotional distress hypothesis of nicotine 
abuse. Further investigation will hopefully be carried along this 
line in the future.
Numerous studies showed antidepressant-like effects of 
nicotine in rat and mouse models, such as in learned helpless-
ness (316) and forced swim tests (311–314, 317). However, some 
authors have observed decreased depression-like phenotypes in 
response to nicotine only in rat strains that display enhanced basal 
levels of depressive features, with contradictory effects depending 
on the post-injection time of the testing (311, 315, 318). As for 
anxiety, factors including age, sex, and genetic background may 
also influence the action of nicotine on mood. One study notably 
demonstrated that while acute nicotine decreased depression-
like behavior in adult Sprague-Dawley rats, it had no effect in 
adolescent rats (285). There is also evidence for decreased depres-
sion-like phenotypes following chronic nicotine exposure (312, 
316). Furthermore, chronic administration of nicotine results 
in an enhanced response to classical antidepressants (314, 366) 
and reverses anhedonia induced by chronic stress (367). Acute 
and chronic exposure to nicotine also had antidepressant effects 
in environmentally induced rat models of depression (357, 
368, 369). Interestingly, chronic oral nicotine intake or repeated 
nicotine injections diminished depressive symptoms more than 
transcranial magnetic stimulation (369). However, one study 
found no depression-like phenotypes in response to chronic 
nicotine in the tail suspension task in male and female rats, 
whatever the dose of nicotine tested (300). By contrast, nicotine 
withdrawal is clearly associated with enhanced depression-like 
behaviors, including elevated reward thresholds (370) in rats. At 
early stages of withdrawal, mice exhibited a depression-like profile 
similar to that observed following a chronic stress regimen (367). 
Acute administration of the antidepressant fluoxetine reversed 
nicotine withdrawal-induced intra-cranial self-stimulation 
threshold elevations when coadministered with a 5-HT1A recep-
tor antagonist (371).
Overall, there is evidence supporting the self-medication 
hypothesis for anxiety and depressive-like symptoms, including 
those resulting from nicotine exposure cessation. Subsequent 
nicotine-seeking relapse may be driven by negative reinforce-
ment mechanisms that anticipate such affective distress (260). 
However, nicotine-elicited improvements of anxiety and mood 
appear to strongly depend on several conditions. Nicotine can 
also deteriorate affective states in some conditions, an important 
fact that may paradoxically contribute to smoking maintenance 
and should be taken in account to provide appropriate smoking 
cessation help.
Cognitive impairments
Accumulating evidence suggests that cognitive enhancement 
may contribute to nicotine addiction through different modali-
ties. Research using experimental animals has provided a better 
understanding of the effects of nicotine on cognitive processes.
Nicotine administration has been shown to improve learning 
and memory (157, 319, 321, 329, 331, 372, 373). Single injec-
tions of nicotine notably improved working memory in rodents 
(157, 320). Acute nicotine administration also enhanced 
acquisition, consolidation, and restitution of the information 
in an object recognition task in rats (319). Yet, it was reported 
that acute nicotine did not improve acquisition in the water 
maze in group housed mice and even impaired performances 
in this task in individually housed mice (322). Importantly, 
many preclinical studies show that the efficacy of nicotine 
on memory does not diminish with chronic administration. 
For instances, chronic nicotine exposure improves memory 
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performances in rats (323–326) or memory consolidation in 
mice (332). Nevertheless, some studies found no effects of 
chronic administration on memory function. Notably, chronic 
nicotine in NMRI male mice did not significantly change per-
formance in the water maze (333). Age may be a significant 
factor influencing the action of nicotine on memory. A study 
reported that nicotine improved the acquisition of a serial pat-
tern learning task in young but not old Fisher 344 rats, while 
no effects were found on reference memory in either group 
(330). Chronic nicotine administration also failed to improve 
working memory in old rats (328). Yet, other studies obtained 
contrasting data with improvements of memory in response 
to nicotine in senescence-accelerated mice (374) and aged 
rats (327). Nicotine also alleviated memory deficits induced 
by chemical or pharmacological agents (375, 376), and brain 
lesions (377, 378). By contrast, nicotine withdrawal resulted 
in learning and memory impairments including in contextual 
fear conditioning (306, 379, 380).
Although these data suggest primary mnemonic effects of nic-
otine, there has been much debate as to whether beneficial effects 
of nicotine in tasks of learning and memory may be secondary to 
effects on attentional functions. A first study reported that small 
doses of nicotine reversed deficits in 5-CSRTT accuracy in basal 
forebrain lesioned rats, but not in non-lesioned animals (381). 
Nevertheless, other studies showed improvements in 5-CSRTT 
response accuracy following acute (266, 334, 338, 339) and 
chronic (271, 274, 340, 341) exposure to nicotine, although these 
effects may be strain dependent (337). Nicotine also induced 
improvements in choice accuracy in a two-choice stimulus 
detection task (335, 336). As observed for learning and memory, 
nicotine reversed attentional impairments caused by brain or 
pharmacologically induced lesions (325, 381, 382). Nicotine 
withdrawal was shown to impair choice accuracy, to increase 
omission errors in the 5-CSRTT (271, 383), and to impair PPI of 
acoustic startle in mice (384), although contrasting results were 
found with another stain of mice (385).
Apart from learning, memory, and attention functions, 
very few studies have focused on the consequences of nicotine 
exposure on executive functions in animals. Some studies have 
evaluated the effects of nicotine on measures of cognitive flex-
ibility. Deficits in cognitive flexibility may contribute to drug 
addiction as the inability to change a response to stimuli previ-
ously associated with a drug stimulus or reward (386). Acute 
nicotine injections impaired decision-making, and this effect 
was associated with deficits in behavioral flexibility measured 
as perseverating responding in rats (342). The same authors 
reported that chronic neonatal nicotine did not impair decision-
making in rats (343). Yet, chronic exposure to a high, but not 
low, dose of nicotine impaired response reversal learning in 
mice (344, 345). In contrast, other authors (346, 347) reported 
that acute and repeated nicotine administration improved 
attentional set-shifting in rats.
CONClUSiON
The studies related across this review strongly support 
the idea that inter-individual differences in cognitive and 
affective processing both preceding and resulting from repeated 
exposure to nicotine contribute to nicotine addiction. There 
is growing evidence that nicotine addiction arises from the 
combined interactions of various processes underlying cogni-
tion and emotion with nicotine exposure according to several 
modalities.
First, human studies, but mostly preclinical investigations, 
clearly indicate that nicotine can have direct facilitator effects 
on cognitive processing and alleviate negative affective states, 
supporting the hypothesis of tobacco smoking as a form of self-
medication. This seems to be particularly the case for memory 
and attention deficits, as well as anxiety and depression-like 
phenotypes. Reversal of such cognitive and affective deficits by 
nicotine is even clearer for withdrawal-associated phenotypes. 
Tobacco smoking may thus also be maintained as a form of 
self-medication in individuals who show moderate cognitive 
or affective impairments and who are not diagnosed with a 
particular psychiatric condition. However, despite demon-
strable nicotine-induced improvements of affective states and 
cognitive deficits, this is only indirect evidence supporting the 
self-medication hypothesis, which should not be considered 
as the only plausible explanation for high rates of smoking 
behavior in psychiatric populations. One should also emphasize 
the fact that chronic exposure to nicotine can also impair 
anxiety and mood in some conditions, to help attenuate 
hesitations in smoking-cessation attempts. Second, pre-existing 
phenotypes, such as high impulsivity and sensation seeking, 
appear to influence the appetence for nicotine according to 
most studies and may drive the propensity for initiating and 
pursuing smoking behavior. However, additional preclinical 
longitudinal studies need to be performed for resolving this 
issue, particularly to investigate the relationship between pre-
disposing phenotypes and behavioral models that still need to 
be developed to truly capture addiction-like features such as 
habitual and compulsive nicotine taking and seeking. Last but 
not least, numerous studies reviewed here show that nicotine 
can trigger “pro-addiction” phenotypes such as impulsivity and 
deficits in cognitive flexibility. Nicotine-induced enhancements 
of learning, memory, and attention may also promote the 
shift toward nicotine addiction by facilitating the associations 
between smoking and contextual cues that underlie habitual 
drug use, craving, and relapse.
The great heterogeneity regarding the effects of nicotine 
observed across the different studies that we reviewed further 
suggests that the underlying reasons for smoking may vary 
across individuals, according to their pre-existing differences 
in genetics, life experiences, tobacco history, or personality traits.
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